|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
2/2021
vol. 96 abstract:
Case report
Successful treatment of infliximab-induced psoriasiform skin lesions despite biologic therapy intensification in a paediatric patient with Crohn’s disease and primary sclerosing cholangitis
Agata Wasilewska
1
,
Małgorzata Chmielowska-Trybek
1
,
Małgorzata Sładek
1
Pediatr Pol 2021; 96 (2): 143–147
Online publish date: 2021/07/01
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Therapy with infliximab (IFX), a tumour necrosis factor-α (TNF-α) inhibitor, has been demonstrated to be highly effective in several immune-mediated inflammatory diseases including Crohn’s disease (CD) and psoriasis, both in adult and paediatric patients. With the increasingly widespread use and longer follow-up of IFX, one unexpected adverse effect that has been reported is the occurrence of psoriasis-like lesions, mainly during the maintenance therapy. The present report was aimed at describing a new case of IFX-induced psoriasis-like lesions in a 17-year-old boy with CD and primary sclerosing cholangitis (PSC), which was successfully treated with topical agents, despite IFX therapy intensification due to loss of the clinical response.
keywords:
infliximab, Crohn’s disease, primary sclerosing cholangitis, paradoxical psoriasis, adverse effects |
POLSKI
